FACTS ABOUT TRACLEER REVEALED

six The phosphodiesterase-5 inhibitor sildenafil is licensed for PAH in FC I–IV inside the United states of america and FC II–III in Europe. Endothelin receptor antagonists (ERAs) like bosentan, sitaxentan and ambrisentan are oral therapies licensed to be used in PAH. As no oral agent has shown superiority there continues to be discussion as to